3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Barrett Esophagus
4
Breast Neoplasms
3
Pancreatic Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Inflammation
2
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Peripheral Nervous System Diseases
1
Obesity
1
Neoplasms
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Colorectal Neoplasia
1
Chemotherapy Effect
1
Breast Neoplasms, Male
1
Interventions
enzalutamide
6
Abiraterone Acetate
5
abiraterone
2
Prednisone
2
pembrolizumab
1
darolutamide
1
cabazitaxel
1
apalutamide
1
TVB-2640
1
Standard of Care
1
Radiosurgery
1
Pluvicto
1
Photons
1
Omeprazole
1
Nivolumab
1
Ipilimumab
1
Gonadotropin-Releasing Hormone
1
Exome Sequencing
1
Drug Therapy
1
CTLA-4 Antigen
1
Artificial Intelligence
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostatic Neoplasms, Castration-Resistant
×
Omeprazole
×
Clear all
NCT04337580
2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2
Recruiting
50 enrolled